C 
China Resources Jiangzhong Pharmaceutical Co 600750.SS · CNY
Health Care · Shanghai · 🇨🇳 China
23.20
-0.04%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥4.22bn
FY2016FY2025
Net income
CN¥906.1m
FY2016FY2025
Free cash flow
CN¥690.3m
FY2016FY2025
Shareholders' equity
CN¥4.02bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥4.22bn | CN¥4.44bn | CN¥4.55bn | CN¥3.89bn | CN¥2.87bn | CN¥2.44bn | CN¥2.45bn | CN¥1.76bn | CN¥1.75bn | CN¥1.55bn |
| Gross profit | CN¥2.76bn | CN¥2.80bn | CN¥2.91bn | CN¥2.50bn | CN¥1.85bn | CN¥1.59bn | CN¥1.63bn | CN¥1.18bn | CN¥1.21bn | CN¥1.10bn |
| Research and development | CN¥152.8m | CN¥130.4m | CN¥141.4m | CN¥100.0m | CN¥87.8m | CN¥55.6m | CN¥47.5m | CN¥29.6m | CN¥22.8m | CN¥54.1m |
| Operating income | CN¥1.02bn | CN¥1.03bn | CN¥912.8m | CN¥748.4m | CN¥626.0m | CN¥573.9m | CN¥567.6m | CN¥548.2m | CN¥483.1m | CN¥445.9m |
| Net income | CN¥906.1m | CN¥788.2m | CN¥718.7m | CN¥598.2m | CN¥505.7m | CN¥473.7m | CN¥463.6m | CN¥470.2m | CN¥417.8m | CN¥379.8m |
| Diluted earnings per share | 1.89 | 1.24 | 0.73 | 0.96 | 0.78 | 0.75 | 0.74 | 0.77 | 0.66 | -24.02 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥6.88bn | CN¥6.51bn | CN¥6.40bn | CN¥6.28bn | CN¥6.00bn | CN¥4.92bn | CN¥4.76bn | CN¥3.82bn | CN¥3.36bn | CN¥3.07bn |
| Cash and short-term investments | CN¥804.2m | CN¥1.02bn | CN¥1.38bn | CN¥2.74bn | CN¥2.77bn | CN¥2.08bn | CN¥1.58bn | CN¥1.01bn | CN¥724.8m | CN¥898.0m |
| Total liabilities | CN¥2.18bn | CN¥2.04bn | CN¥1.77bn | CN¥1.77bn | CN¥1.42bn | CN¥672.3m | CN¥834.8m | CN¥563.5m | CN¥448.7m | CN¥450.0m |
| Debt | CN¥355.4m | CN¥108,811 | CN¥57.7m | CN¥90.3m | CN¥4.5m | CN¥297,036 | — | CN¥20.0m | CN¥70.0m | CN¥30.0m |
| Shareholders' equity | CN¥4.02bn | CN¥3.86bn | CN¥3.91bn | CN¥3.89bn | CN¥4.00bn | CN¥3.88bn | CN¥3.56bn | CN¥3.25bn | CN¥2.92bn | CN¥2.62bn |
| Shares outstanding | 480m | 638m | 984m | 625m | 646m | 631m | 629m | 608m | 632m | — |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥970.9m | CN¥786.3m | CN¥1.04bn | CN¥1.02bn | CN¥917.0m | CN¥752.5m | CN¥641.2m | CN¥486.2m | CN¥124.9m | CN¥698.0m |
| Capital spending | −CN¥280.6m | −CN¥290.8m | −CN¥208.9m | −CN¥345.6m | −CN¥188.5m | −CN¥182.5m | −CN¥76.3m | −CN¥121.4m | −CN¥181.2m | −CN¥70.1m |
| Free cash flow | CN¥690.3m | CN¥495.5m | CN¥827.0m | CN¥676.1m | CN¥728.5m | CN¥570.0m | CN¥564.8m | CN¥364.9m | −CN¥56.3m | CN¥628.0m |
| Dividends paid | −CN¥778.0m | −CN¥768.5m | −CN¥800.5m | −CN¥733.1m | −CN¥308.7m | −CN¥163.4m | −CN¥147.0m | −CN¥135.0m | −CN¥120.9m | −CN¥123.8m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥896.1m | CN¥1.04bn | CN¥1.29bn | CN¥792.1m | CN¥957.0m | CN¥1.18bn | CN¥1.46bn | CN¥857.1m |
| Gross profit | CN¥583.4m | CN¥705.9m | CN¥820.8m | CN¥501.8m | CN¥627.9m | CN¥807.7m | CN¥790.3m | CN¥537.3m |
| Operating income | CN¥245.4m | CN¥335.7m | CN¥101.7m | CN¥217.5m | CN¥341.7m | CN¥359.2m | CN¥221.4m | CN¥198.6m |
| Net income | CN¥203.4m | CN¥288.0m | CN¥223.2m | CN¥161.1m | CN¥237.4m | CN¥284.9m | CN¥153.9m | CN¥153.9m |
| Diluted earnings per share | 0.42 | 0.60 | 0.47 | 0.34 | 0.49 | 0.59 | 0.24 | 0.24 |
| Cash from operations | — | — | −CN¥2.0m | CN¥326.0m | CN¥478.0m | CN¥194.0m | CN¥343.0m | −CN¥32.0m |
| Capital spending | −CN¥51.0m | −CN¥50.0m | −CN¥77.0m | −CN¥95.0m | −CN¥61.0m | −CN¥46.0m | −CN¥142.0m | −CN¥57.0m |
| Free cash flow | — | — | −CN¥79.0m | CN¥231.0m | CN¥417.0m | CN¥148.0m | CN¥201.0m | −CN¥89.0m |
| Total assets | CN¥6.74bn | CN¥7.16bn | CN¥6.88bn | CN¥6.89bn | CN¥6.64bn | CN¥6.68bn | CN¥6.51bn | CN¥6.13bn |
| Cash and short-term investments | — | — | CN¥804.2m | CN¥2.11bn | CN¥1.68bn | CN¥1.72bn | CN¥1.02bn | CN¥908.0m |
| Debt | — | — | CN¥354.3m | CN¥475.4m | CN¥334.2m | CN¥1.1m | CN¥6.2m | CN¥665,253 |
| Shareholders' equity | CN¥3.96bn | CN¥4.32bn | CN¥4.02bn | CN¥3.80bn | CN¥3.95bn | CN¥4.15bn | CN¥3.86bn | CN¥3.72bn |
Financial ratios
Data as of 30 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 65.4% | 63.2% | 63.8% | 64.4% | 64.3% | 65.3% |
| Operating margin | 24.2% | 23.2% | 20.0% | 19.3% | 21.8% | 23.5% |
| Net margin | 21.5% | 17.8% | 15.8% | 15.4% | 17.6% | 19.4% |
| Return on equity | 22.5% | 20.4% | 18.4% | 15.4% | 12.6% | 12.2% |
| Return on assets | 13.2% | 12.1% | 11.2% | 9.5% | 8.4% | 9.6% |
| Free cash flow yield | 11.6% | 7.5% | 5.6% | 9.7% | 7.6% | 6.6% |
| Revenue growth | -4.9% | -2.6% | 17.2% | 35.2% | 17.7% | -0.3% |
| Earnings growth | 15.0% | 9.7% | 20.1% | 18.3% | 6.7% | 2.2% |
| Current ratio | 1.80x | 1.40x | 1.54x | 2.42x | 3.09x | 5.45x |
| Debt to equity | 0.09x | 0.00x | 0.01x | 0.02x | 0.00x | 0.00x |
| Equity ratio | 58.5% | 59.4% | 61.1% | 62.0% | 66.7% | 78.7% |
| Interest coverage | 386.26x | 476.91x | 116.52x | 148.58x | 161.52x | 297.66x |
| R&D as a share of sales | 3.6% | 2.9% | 3.1% | 2.6% | 3.1% | 2.3% |
| Buybacks as a share of market value | 24.8% | 35.2% | -57.4% | 3.2% | -2.3% | -0.3% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 2.8% | 11.6% | 5.0% |
| Operating income | 10.9% | 12.2% | 9.0% |
| Net income | 14.8% | 13.8% | 9.5% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 64.2% | 64.2% | 64.3% | 64.0% |
| Operating margin | 23.7% | 21.7% | 21.9% | 22.7% |
| Net margin | 19.6% | 17.6% | 17.8% | 18.7% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 12.3 | 18.4 | 28.6 | 15.1 | 18.4 | 14.1 | 14.2 | 14.6 | 18.3 | -0.6 |
| Price to sales | 2.6 | 3.3 | 4.5 | 2.3 | 3.3 | 2.7 | 2.7 | 3.9 | 4.4 | -0.1 |
Dividends and splits
Per share, in the currency the company pays
Paid for 25 years. Last went ex-dividend on 22 Jun 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.88 | 1.20 | 1.20 | 1.25 | 1.15 | 0.49 | 0.25 | 0.233 |
- 6-for-5 split · 12 Jun 2020
- 5-for-4 split · 12 Jun 2019
- 7-for-5 split · 20 Jun 2018
- 1.35-for-1 split · 27 Aug 2007
- 3-for-2 split · 24 May 2007
- 1-to-1 reverse split · 17 May 2006
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.